Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective Inhibitors of G2019S-LRRK2 Kinase Activity.
Garofalo AW, Bright J, De Lombaert S, Toda AMA, Zobel K, Andreotti D, Beato C, Bernardi S, Budassi F, Caberlotto L, Gao P, Griffante C, Liu X, Mengatto L, Migliore M, Sabbatini FM, Sava A, Serra E, Vincetti P, Zhang M, Carlisle HJ. Garofalo AW, et al. Among authors: sava a. J Med Chem. 2020 Dec 10;63(23):14821-14839. doi: 10.1021/acs.jmedchem.0c01243. Epub 2020 Nov 16. J Med Chem. 2020. PMID: 33197196
Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists.
Micheli F, Cremonesi S, Semeraro T, Tarsi L, Tomelleri S, Cavanni P, Oliosi B, Perdonà E, Sava A, Zonzini L, Feriani A, Braggio S, Heidbreder C. Micheli F, et al. Among authors: sava a. Bioorg Med Chem Lett. 2016 Feb 15;26(4):1329-32. doi: 10.1016/j.bmcl.2015.12.081. Epub 2016 Jan 5. Bioorg Med Chem Lett. 2016. PMID: 26786693
1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.
Micheli F, Bacchi A, Braggio S, Castelletti L, Cavallini P, Cavanni P, Cremonesi S, Dal Cin M, Feriani A, Gehanne S, Kajbaf M, Marchió L, Nola S, Oliosi B, Pellacani A, Perdonà E, Sava A, Semeraro T, Tarsi L, Tomelleri S, Wong A, Visentini F, Zonzini L, Heidbreder C. Micheli F, et al. Among authors: sava a. J Med Chem. 2016 Sep 22;59(18):8549-76. doi: 10.1021/acs.jmedchem.6b00972. Epub 2016 Sep 9. J Med Chem. 2016. PMID: 27564135
Brain-penetrant cyanoindane and cyanotetralin inhibitors of G2019S-LRRK2 kinase activity.
Garofalo AW, Schwarz J, Zobel K, Beato C, Bernardi S, Budassi F, Caberlotto L, Gao P, Griffante C, Liu X, Migliore M, Qiao F, Sabbatini FM, Sava A, Zhang M, Carlisle HJ. Garofalo AW, et al. Among authors: sava a. Bioorg Med Chem Lett. 2023 Oct 15;95:129487. doi: 10.1016/j.bmcl.2023.129487. Epub 2023 Sep 19. Bioorg Med Chem Lett. 2023. PMID: 37734423
Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.
Gianotti M, Botta M, Brough S, Carletti R, Castiglioni E, Corti C, Dal-Cin M, Delle Fratte S, Korajac D, Lovric M, Merlo G, Mesic M, Pavone F, Piccoli L, Rast S, Roscic M, Sava A, Smehil M, Stasi L, Togninelli A, Wigglesworth MJ. Gianotti M, et al. Among authors: sava a. J Med Chem. 2010 Nov 11;53(21):7778-95. doi: 10.1021/jm100856p. J Med Chem. 2010. PMID: 20942472
The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2.
D'Alessandro PL, Corti C, Roth A, Ugolini A, Sava A, Montanari D, Bianchi F, Garland SL, Powney B, Koppe EL, Rocheville M, Osborne G, Perez P, de la Fuente J, De Los Frailes M, Smith PW, Branch C, Nash D, Watson SP. D'Alessandro PL, et al. Among authors: sava a. Bioorg Med Chem Lett. 2010 Jan 15;20(2):759-62. doi: 10.1016/j.bmcl.2009.11.032. Epub 2009 Nov 26. Bioorg Med Chem Lett. 2010. PMID: 20005096
104 results